AXSM
Axsome Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▼ 2 insiders sell $9.8M at $161.56
- Apr 22 ▼ 1 insider sell $1.4M at $182.42
- Apr 30 ▲ Axsome Therapeutics announced FDA approval of AUVELITY for agitation…
- May 1 ▲ Axsome Therapeutics announced FDA approval of AUVELITY for agitation…
- May 4 to May 5 ▼ 2 days of insider sells: $1.1M by 1 insider, avg $227.95
- May 29 to Jun 11 ▼ 6 days of insider sells: $24.4M by 5 insiders, avg $238.77
- Jul 1 ▼ 1 insider sell $11.9M at $240.25
- Jul 7 FDA: Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Sol…
- Jul 9 In Re Axsome Therapeutics, Inc. Stockholder Derivative…
- Jul 21 BMO Capital initiates
- Aug 5 to Aug 6 ▼ 2 days of insider sells: $10.5M by 1 insider, avg $212.19
- Sep 3 ▼ 1 insider sell $2.1M at $208.65
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $61.1M.
- InstitutionsMIXED
Q3 2026: 37 added (0 new), 37 trimmed or exited.
- AnalystsBULLISH
27 of 29 rate it Buy or better.
- Short sellersSTEADY
Short interest +4.9% to 3.26M shares. 3.4 days to cover, ≈6.2% of shares.
- TrendDOWNTREND
19% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $156.7M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | DOUBLED | $133.8M |
| MORGAN STANLEY | TRIM | $109.1M |
| FEDERATED HERMES, INC. | DOUBLED | $88.9M |
| Assenagon Asset Management S.A. | TRIM | $46.2M |
| DEUTSCHE BANK AG\ | ADD | $31.4M |
| Aberdeen Group plc | ADD | $21.7M |
| RAYMOND JAMES FINANCIAL INC | TRIM | $19.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
29 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 4, 2026 | Mizuho MAINTAIN | Outperform |
| Nov 3, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 3, 2026 | UBS MAINTAIN | Buy |
| Nov 3, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 3, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Jacobson Mark L. Chief Operating Officer Sep 3, 2026 | SELL | $2.1M |
Jacobson Mark L. Chief Operating Officer Sep 3, 2026 | EXERCISE | $129.5K |
TABUTEAU HERRIOT Chief Executive Officer Aug 6, 2026 | SELL | $997.0K |
TABUTEAU HERRIOT Chief Executive Officer Aug 6, 2026 | EXERCISE | $23.1K |
TABUTEAU HERRIOT Chief Executive Officer Aug 5, 2026 | EXERCISE | $222.8K |
TABUTEAU HERRIOT Chief Executive Officer Aug 5, 2026 | SELL | $9.5M |
TABUTEAU HERRIOT Chief Executive Officer Jul 1, 2026 | EXERCISE | $245.8K |
TABUTEAU HERRIOT Chief Executive Officer Jul 1, 2026 | SELL | $11.9M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 6 press releases · 5 bullish · 1 bearish · 4 mixed · 10 neutral- BULLISH 8-KNov 2, 2026
Axsome reported Q3 2026 net product revenue of $259.7M (+52% YoY), driven by AUVELITY sales of…
The sharp narrowing of net loss combined with accelerating prescription growth for AUVELITY in the Alzheimer's agitation indication suggests the company is approaching cash flow positivity faster…
- BULLISH PRESS-RELEASENov 2, 2026
Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M, 52% YoY growth, beating the…
The strong revenue beat and narrowing losses support the company's path to profitability. Key catalysts ahead include the AXS-12 PDUFA decision in May 2027 and multiple Phase 3 readouts in 2027…
- BEARISH INST-CLUSTEROct 20, 2026
Three institutional asset managers trimmed or exited AXSM positions in Q3 2026, led by Assenagon…
The concentrated selling by three active asset managers, especially Assenagon's $65M trim, signals a coordinated negative view. Monitor for any fundamental catalyst (pipeline update, revenue miss…
- MIXED INST-CLUSTERAug 11, 2026
Q2 2026 13F cluster for Axsome Therapeutics shows a mixed institutional picture: 9 smaller buyers…
The institutional cluster is mixed but net bearish in dollar terms, with large holders trimming while smaller funds add. The Q2 earnings showed strong top-line growth but expanding losses, and the…
All AXSM filing & press-release reports (26)
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- INST-CLUSTER reportOct 20, 2026
- INST-CLUSTER reportAug 11, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportJul 15, 2026
- COURT-RULING reportJul 9, 2026
- PRESS-RELEASE reportJul 7, 2026
- 144 reportJul 1, 2026
- PRESS-RELEASE reportJun 15, 2026
- CLUSTER reportJun 11, 2026
- 144 reportJun 11, 2026
- CLUSTER reportJun 10, 2026
- 144 reportJun 9, 2026
- 8-K reportJun 9, 2026
- CLUSTER reportJun 9, 2026
- PRESS-RELEASE reportJun 4, 2026
- 8-K reportJun 3, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportMay 1, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- DEFA14A reportApr 24, 2026
- PRESS-RELEASE reportApr 8, 2026